3BAE

Crystal structure of Fab WO2 bound to the N terminal domain of Amyloid beta peptide (1-28)


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.593 Å
  • R-Value Free: 0.250 
  • R-Value Work: 0.207 

wwPDB Validation 3D Report Full Report


This is version 1.1 of the entry. See complete history

Literature

Amyloid-beta-anti-amyloid-beta complex structure reveals an extended conformation in the immunodominant B-cell epitope.

Miles, L.A.Wun, K.S.Crespi, G.A.Fodero-Tavoletti, M.T.Galatis, D.Bagley, C.J.Beyreuther, K.Masters, C.L.Cappai, R.McKinstry, W.J.Barnham, K.J.Parker, M.W.

(2008) J.Mol.Biol. 377: 181-192

  • DOI: 10.1016/j.jmb.2007.12.036
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 
  • Alzheimer's disease (AD) is the most common form of dementia. Amyloid-beta (A beta) peptide, generated by proteolytic cleavage of the amyloid precursor protein, is central to AD pathogenesis. Most pharmaceutical activity in AD research has focused on ...

    Alzheimer's disease (AD) is the most common form of dementia. Amyloid-beta (A beta) peptide, generated by proteolytic cleavage of the amyloid precursor protein, is central to AD pathogenesis. Most pharmaceutical activity in AD research has focused on A beta, its generation and clearance from the brain. In particular, there is much interest in immunotherapy approaches with a number of anti-A beta antibodies in clinical trials. We have developed a monoclonal antibody, called WO2, which recognises the A beta peptide. To this end, we have determined the three-dimensional structure, to near atomic resolution, of both the antibody and the complex with its antigen, the A beta peptide. The structures reveal the molecular basis for WO2 recognition and binding of A beta. The A beta peptide adopts an extended, coil-like conformation across its major immunodominant B-cell epitope between residues 2 and 8. We have also studied the antibody-bound A beta peptide in the presence of metals known to affect its aggregation state and show that WO2 inhibits these interactions. Thus, antibodies that target the N-terminal region of A beta, such as WO2, hold promise for therapeutic development.


    Organizational Affiliation

    Biota Structural Biology Laboratory, St. Vincent's Institute of Medical Research, 9 Princes Street, Fitzroy, Victoria 3065, Australia.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
WO2 IgG2a Fab fragment Light Chain Kappa
L
218Mus musculusMutation(s): 0 
Gene Names: Igkc (Igk-C)
Find proteins for A2NHM3 (Mus musculus)
Go to UniProtKB:  A2NHM3
Entity ID: 2
MoleculeChainsSequence LengthOrganismDetails
WO2 IgG2a Fab fragment Heavy Chain
H
228Mus musculusMutation(s): 0 
Find proteins for Q811U5 (Mus musculus)
Go to UniProtKB:  Q811U5
Entity ID: 3
MoleculeChainsSequence LengthOrganismDetails
Amyloid Beta Peptide
A
28Homo sapiensMutation(s): 0 
Gene Names: APP (A4, AD1)
Find proteins for P05067 (Homo sapiens)
Go to Gene View: APP
Go to UniProtKB:  P05067
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.593 Å
  • R-Value Free: 0.250 
  • R-Value Work: 0.207 
  • Space Group: P 21 21 21
Unit Cell:
Length (Å)Angle (°)
a = 51.658α = 90.00
b = 66.365β = 90.00
c = 115.337γ = 90.00
Software Package:
Software NamePurpose
REFMACrefinement
SCALAdata scaling
PDB_EXTRACTdata extraction
d*TREKdata scaling
CrystalCleardata collection
MOSFLMdata reduction
MOLREPphasing

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

Revision History 

  • Version 1.0: 2008-04-15
    Type: Initial release
  • Version 1.1: 2011-07-13
    Type: Version format compliance